Sign In
Buy SAGE
$8.68
+0 (+0%)
At Close: Oct 30, 2025
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Sage Therapeutics, Inc. (SAGE)
12:00pm, Wednesday, 09'th Oct 2024
LOS ANGELES, Oct. 09, 2024 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming October 28, 2024 deadline to file a lead plaintiff motion in the class action
NEW YORK, NY / ACCESSWIRE / October 9, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities
Sage Therapeutics, Inc. Is Being Sued For Violating Securities Laws And Affected Shareholders Are Urged To Contact The Schall Law Firm
11:00am, Wednesday, 09'th Oct 2024
LOS ANGELES, CA / ACCESSWIRE / October 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sage Therapeutics, Inc. ("Sage"
NEW YORK, NY / ACCESSWIRE / October 9, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Sage To Contact Him Directly To Discuss Their Options If you suffer
NEW YORK, NY / ACCESSWIRE / October 9, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities
NEW YORK CITY, NY / ACCESSWIRE / October 9, 2024 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Sage Ther
NEW YORK, NY / ACCESSWIRE / October 8, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities
NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sage Therapeutics, Inc. (NASDAQ: SAGE).
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Sage Therapeutics, Inc. Lawsuit - SAGE
11:30am, Tuesday, 08'th Oct 2024
NEW YORK, NY / ACCESSWIRE / October 8, 2024 / If you suffered a loss on your Sage Therapeutics, Inc. (NASDAQ:SAGE) investment and want to learn about a potential recovery under the federal securities
The Schall Law Firm Encourages Investor Participation In A Securities Fraud Case Against Sage Therapeutics Inc
11:00am, Tuesday, 08'th Oct 2024
LOS ANGELES, CA / ACCESSWIRE / October 8, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sage Therapeutics, Inc. ("Sage"
SAGE Stock Volatile After Alzheimer's Drug Development Halt
10:52am, Tuesday, 08'th Oct 2024
Sage Therapeutics (SAGE, Financial) experienced significant stock price fluctuations recently. Initially, the stock fell over 13% but later recovered, trading at a 0.5% gain to $6.756.
Sage Therapeutics (SAGE) Shares Fall Following Alzheimer's Drug Trial Failure
09:30am, Tuesday, 08'th Oct 2024
Sage Therapeutics (SAGE, Financial) reported a significant drop in its stock price, falling more than 30% in pre-market trading. It later stabilized at an 11% decline.
After Disappointing Parkinson's Data, Sage Therapeutics' Dalzanemdor Flunks Mid-Stage Alzheimer's Study
09:19am, Tuesday, 08'th Oct 2024
Tuesday, Sage Therapeutics, Inc. SAGE released topline results from the Phase 2 LIGHTWAVE study to evaluate the effects of dalzanemdor (SAGE-718) in participants with mild cognitive impairment (MCI)
Sage Therapeutics Stock Plunges on Disappointing Study Results for Alzheimer's Treatment
07:36am, Tuesday, 08'th Oct 2024
The biopharmaceutical company isn't planning further clinical development of dalzanemdor to treat Alzheimer's.
